Canandaigua National Trust Co of Florida Purchases 263 Shares of Johnson & Johnson (NYSE:JNJ)

Canandaigua National Trust Co of Florida lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,250 shares of the company’s stock after acquiring an additional 263 shares during the quarter. Canandaigua National Trust Co of Florida’s holdings in Johnson & Johnson were worth $325,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Capital Market Strategies LLC increased its position in Johnson & Johnson by 5.8% during the 4th quarter. Capital Market Strategies LLC now owns 7,723 shares of the company’s stock valued at $1,117,000 after purchasing an additional 425 shares during the period. Pensionfund Sabic raised its stake in Johnson & Johnson by 49.2% in the fourth quarter. Pensionfund Sabic now owns 27,300 shares of the company’s stock worth $3,948,000 after buying an additional 9,000 shares in the last quarter. Nordea Investment Management AB lifted its holdings in Johnson & Johnson by 13.7% during the fourth quarter. Nordea Investment Management AB now owns 6,424,675 shares of the company’s stock worth $926,438,000 after buying an additional 775,490 shares during the period. Versant Capital Management Inc increased its holdings in shares of Johnson & Johnson by 27.8% in the 4th quarter. Versant Capital Management Inc now owns 4,678 shares of the company’s stock valued at $677,000 after acquiring an additional 1,019 shares during the period. Finally, Trust Co of the South raised its position in shares of Johnson & Johnson by 5.1% in the 4th quarter. Trust Co of the South now owns 9,672 shares of the company’s stock worth $1,399,000 after acquiring an additional 470 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.6 %

Shares of JNJ stock traded down $0.81 during trading on Monday, hitting $143.38. 7,907,418 shares of the stock traded hands, compared to its average volume of 5,727,147. The firm’s fifty day moving average price is $151.40 and its 200-day moving average price is $156.28. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $345.20 billion, a P/E ratio of 20.75, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 52-week low of $142.75 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company earned $2.66 EPS. As a group, research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Guggenheim upped their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.